Cargando…
The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion
BACKGROUND: The Medicare Prescription Drug, Improvement, and Modernization Act, signed into law in 2003, provided access to prescription drugs for elderly Americans. The Part D benefit continues to evolve. Changes in plan designs, he impact of the doughnut hole on beneficiaries, and increased cost s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437764/ https://www.ncbi.nlm.nih.gov/pubmed/19125557 http://dx.doi.org/10.18553/jmcp.2009.15.s1.18 |
_version_ | 1785092607750176768 |
---|---|
author | Balfour III, Donald C. Evans, Steven Januska, Jeff Lee, Helen Y. Lewis, Sonya J. Nolan, Steve R. Noga, Mark Stemple, Charles Thapar, Kishan |
author_facet | Balfour III, Donald C. Evans, Steven Januska, Jeff Lee, Helen Y. Lewis, Sonya J. Nolan, Steve R. Noga, Mark Stemple, Charles Thapar, Kishan |
author_sort | Balfour III, Donald C. |
collection | PubMed |
description | BACKGROUND: The Medicare Prescription Drug, Improvement, and Modernization Act, signed into law in 2003, provided access to prescription drugs for elderly Americans. The Part D benefit continues to evolve. Changes in plan designs, he impact of the doughnut hole on beneficiaries, and increased cost shifting have the potential to hamper the future of the Part D benefit. OBJECTIVES: To discuss factors that will likely have the most impact on the future of Medicare Part D from a patient and payer perspective. SUMMARY: The continued growth of the elderly population is expected to place an increasing burden on the services provided through Medicare. Given the current financial situation, it has been predicted that Medicare's Hospital Insurance Trust Fund will be depleted by 2019. To provide quality benefits and remain competitive, health plans are continually evaluating and redesigning their Part D benefits. However, the current regulatory environment is preventing plans from offering nnovative products and designs that could lower costs to beneficiaries. The growing number of beneficiaries hitting the doughnut hole is also becoming a concern for both beneficiaries and health plans. More beneficiaries are reaching the doughnut hole, and this has resulted in changes in beneficiary behaviors, including stopping medications, switching to alternative drug classes, and reducing medication use. Because of the increasing concerns about Medicare's sustainability, it is anticipated that the government may become more involved. CONCLUSIONS: As the health care landscape continues to change, payers will be challenged to offer benefit designs that are affordable to elderly beneficiaries. For its part, the government must allow plans to design benefits that will improve the overall quality of care. Additionally, closer attention must be given to the growing number of beneficiaries hitting the doughnut hole and its potential adverse clinical and economic consequences. |
format | Online Article Text |
id | pubmed-10437764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-104377642023-08-21 The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion Balfour III, Donald C. Evans, Steven Januska, Jeff Lee, Helen Y. Lewis, Sonya J. Nolan, Steve R. Noga, Mark Stemple, Charles Thapar, Kishan J Manag Care Pharm Cea BACKGROUND: The Medicare Prescription Drug, Improvement, and Modernization Act, signed into law in 2003, provided access to prescription drugs for elderly Americans. The Part D benefit continues to evolve. Changes in plan designs, he impact of the doughnut hole on beneficiaries, and increased cost shifting have the potential to hamper the future of the Part D benefit. OBJECTIVES: To discuss factors that will likely have the most impact on the future of Medicare Part D from a patient and payer perspective. SUMMARY: The continued growth of the elderly population is expected to place an increasing burden on the services provided through Medicare. Given the current financial situation, it has been predicted that Medicare's Hospital Insurance Trust Fund will be depleted by 2019. To provide quality benefits and remain competitive, health plans are continually evaluating and redesigning their Part D benefits. However, the current regulatory environment is preventing plans from offering nnovative products and designs that could lower costs to beneficiaries. The growing number of beneficiaries hitting the doughnut hole is also becoming a concern for both beneficiaries and health plans. More beneficiaries are reaching the doughnut hole, and this has resulted in changes in beneficiary behaviors, including stopping medications, switching to alternative drug classes, and reducing medication use. Because of the increasing concerns about Medicare's sustainability, it is anticipated that the government may become more involved. CONCLUSIONS: As the health care landscape continues to change, payers will be challenged to offer benefit designs that are affordable to elderly beneficiaries. For its part, the government must allow plans to design benefits that will improve the overall quality of care. Additionally, closer attention must be given to the growing number of beneficiaries hitting the doughnut hole and its potential adverse clinical and economic consequences. Academy of Managed Care Pharmacy 2009-01 /pmc/articles/PMC10437764/ /pubmed/19125557 http://dx.doi.org/10.18553/jmcp.2009.15.s1.18 Text en Copyright © 2009, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cea Balfour III, Donald C. Evans, Steven Januska, Jeff Lee, Helen Y. Lewis, Sonya J. Nolan, Steve R. Noga, Mark Stemple, Charles Thapar, Kishan The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion |
title | The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion |
title_full | The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion |
title_fullStr | The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion |
title_full_unstemmed | The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion |
title_short | The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion |
title_sort | future of medicare part d drug plans—results from a roundtable discussion |
topic | Cea |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437764/ https://www.ncbi.nlm.nih.gov/pubmed/19125557 http://dx.doi.org/10.18553/jmcp.2009.15.s1.18 |
work_keys_str_mv | AT balfouriiidonaldc thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT evanssteven thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT januskajeff thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT leeheleny thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT lewissonyaj thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT nolanstever thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT nogamark thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT stemplecharles thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT thaparkishan thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion AT balfouriiidonaldc futureofmedicarepartddrugplansresultsfromaroundtablediscussion AT evanssteven futureofmedicarepartddrugplansresultsfromaroundtablediscussion AT januskajeff futureofmedicarepartddrugplansresultsfromaroundtablediscussion AT leeheleny futureofmedicarepartddrugplansresultsfromaroundtablediscussion AT lewissonyaj futureofmedicarepartddrugplansresultsfromaroundtablediscussion AT nolanstever futureofmedicarepartddrugplansresultsfromaroundtablediscussion AT nogamark futureofmedicarepartddrugplansresultsfromaroundtablediscussion AT stemplecharles futureofmedicarepartddrugplansresultsfromaroundtablediscussion AT thaparkishan futureofmedicarepartddrugplansresultsfromaroundtablediscussion |